Home/Pipeline/Pentasa (Mesalazine)

Pentasa (Mesalazine)

Ulcerative Colitis

Approved/CommercialMarketed

Key Facts

Indication

Ulcerative Colitis

Phase

Approved/Commercial

Status

Marketed

Company

Zeria Pharmaceutical

About Zeria Pharmaceutical

Zeria Pharmaceutical is a mid-sized, established Japanese pharmaceutical company with a history spanning over 70 years. It has built a stable business foundation through a multi-pronged strategy involving in-house development, strategic licensing, and marketing of both prescription and consumer health products. The company's strategic direction focuses on strengthening its core gastroenterology franchise while expanding into new therapeutic areas like dermatology and pursuing growth in Asian markets.

View full company profile

Therapeutic Areas

Gastroenterology Dermatology Metabolic Disorders Consumer Health

Other Ulcerative Colitis Drugs

Drug	Company	Phase	Status
Mirikizumab	Eli Lilly	Phase 3	Active
Filgotinib	Gilead Sciences	Phase 3	Active
Obefazimod (ABX464)	Abivax	Phase 3	Active
Icotrokinra (JNJ-2113)	Protagonist Therapeutics	Phase 3	ICONIC-UC initiated Q4 2025
DE-130 (Etrasimod)	Rohto Pharmaceutical	Phase 3	Active
DE-122 (Carotegrast methyl)	Rohto Pharmaceutical	Phase 3	Active
Methylene Blue MMX®	Cosmo Pharmaceuticals	Preclinical	Research
KRP-203 (Amiselimod)	Kissei Pharmaceutical	Phase II	Active
EVO301	Evommune	Phase 1	Not Specified
SER-301	Seres Therapeutics	Phase 1b	Active
SER-287	Seres Therapeutics	Phase 2b	Completed
IMP731	Immutep	Phase 2	Completed